How Komzifti Is Rewriting The Kura Oncology (KURA) Story For Analysts And Investors [Yahoo! Finance]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Yahoo! Finance
now sits at US$30, reflecting how the approval and early launch expectations are feeding into fresh models. Assumptions have been refined, with a discount rate of 7.0544769962281535% and revenue growth of 53.02638371256505% now plugged into scenarios that weigh both the opportunity from Komzifti and the execution risk around its roll out. As you read on, keep an eye on how these moving pieces shape the stock's story so you can stay tuned for practical ways to track changes in this narrative over time. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Kura Oncology. ?? Bullish Takeaways BofA analyst Jason Zemansky raised the Kura Oncology price target to US$30 from US$29 after the FDA approval of ziftomenib, now branded as Komzifti, and keeps a Buy rating, which anchors one of the more optimistic views on the stock. BofA describes the Komzifti approval as a "watershed moment for the company," reflecting confiden
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones [Yahoo! Finance]Yahoo! Finance
- Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 MilestonesGlobeNewswire
- Syncromune Continues to Strengthen Executive and Clinical Leadership with Appointment of Dr. Stephen P. Dale, M.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Jim Cramer Discusses Kura Oncology as a Speculative Bet [Yahoo! Finance]Yahoo! Finance
KURA
Earnings
- 11/4/25 - Miss
KURA
Sec Filings
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- KURA's page on the SEC website